If you have Hodgkin Lymphoma, you can help by completing our survey!

Lymphoma Canada is preparing a submission for the pan-Canadian Oncology Drug Review (pCODR). This survey provides us with the patient input that is required for the submission. pCODR then uses this information to make recommendations to the provinces and territories regarding funding for new cancer drugs.

The upcoming review is for Relapsed/Refractory Hodgkin Lymphoma Patient Experience with Pembrolizumab.

You can still participate in this survey if you have not received this therapy. You also do not need to have relapsed or refractory HL to participate.

You do not need to live in Canada to complete this survey.

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

The survey will be open until midnight Pacific Time on Wednesday, January 13, 2021, and should only take between 15-20 minutes of your time.

You may access the survey by clicking the button below.

Please share and help us spread the word.

Thank you for your support.